Milestone Scientific (MLSS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Jun, 2026Executive summary
Annual Meeting scheduled for July 27, 2026, to be held virtually, with shareholders able to vote and submit questions online.
Key proposals include director elections, amendments to increase authorized shares and equity plan shares, say-on-pay, and auditor ratification.
Proxy materials are distributed electronically to reduce costs and environmental impact.
Forward-looking statements are included, with risks referenced in prior SEC filings.
Voting matters and shareholder proposals
Shareholders will vote on: (1) election of five directors, (2) amendment to increase authorized common shares from 125M to 135M, (3) amendment to increase shares under the 2020 Equity Incentive Plan from 11.5M to 28.75M, (4) advisory say-on-pay, (5) ratification of Grassi & Co. as auditors, and (6) other business.
Each proposal has specific voting requirements; only auditor ratification is considered a routine matter for broker voting.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Five nominees for director: Benedetta Casamento (Chair), Neal Goldman (Vice Chair), Eric Hines (CEO), Dr. Didier Demesmin, and Dr. Dawood Sayed.
Board structure separates Chairman and CEO roles for effective governance.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, each with defined charters and independent members.
Board independence confirmed for three directors; director candidates evaluated on integrity, experience, and fit.
Latest events from Milestone Scientific
- Virtual meeting to vote on directors, share increases, equity plan, pay, and auditor ratification.MLSS
Proxy filing5 Jun 2026 - Resale registration for 15.9M shares after $2.15M private placement; faces funding and compliance risks.MLSS
Registration filing2 Jun 2026 - Q1 2026 saw stable revenue, sharply reduced losses, and improved liquidity amid ongoing risks.MLSS
Q1 202615 May 2026 - 2026 guidance projects double-digit growth and major CompuFlo gains, targeting break even by 2027.MLSS
Q4 20251 Apr 2026 - Q2 net income turned positive on a $2M NOL sale, with strong e-commerce and margin gains.MLSS
Q2 20241 Feb 2026 - Expanding into the $2B epidural market with patented tech, strong margins, and new Medicare coverage.MLSS
Lytham Partners Fall 2024 Investor Conference20 Jan 2026 - Commercialization accelerates with Medicare pricing, new partnerships, and strong clinical impact.MLSS
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Q3 revenue up 22% with strong dental growth, regulatory wins, and improved net loss.MLSS
Q3 202413 Jan 2026 - Virtual meeting to elect directors, ratify auditor, and review governance and compensation.MLSS
Proxy Filing1 Dec 2025